Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Gastrointestinal: Esophagus

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: PENDING
Principal Investigator: Petrich

An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate Bay 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2

The purpose of this study is to evaluate the safety, tolerability (the effect of the study drug on the body), of BAY 1187982 when given as a single agent in patients with advance or refractory (has not responded to other treatment) solid tumors.

Status: Accepting New Patients
Principal Investigator: Kalyan

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given alone or in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).

Status: Accepting New Patients
Principal Investigator: Chae

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Raizer

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYl719 in Adult Patients with Selected Advanced Solid Tumors

The main purpose of this study is to see what effect, good and/or bad, MEK162 and BYL719 given together has on certain advanced solid tumors.

Status: Accepting New Patients
Principal Investigator: Chae

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Kumthekar

last updated: Thu - September 03, 2015 - 02:08 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.